Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 9;13(12):881.
doi: 10.3390/toxins13120881.

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies

Nicola Tambasco  1   2 , Marta Filidei  2 , Pasquale Nigro  1 , Lucilla Parnetti  2 , Simone Simoni  2
Affiliations
Review

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies

Nicola Tambasco et al. Toxins (Basel). .

Abstract

Hemifacial spasm (HFS) is a movement disorder characterized by involuntary contractions of the facial muscles innervated by the seventh cranial nerve. Generally, it is associated with a poor quality of life due to social embarrassment and can lead to functional blindness. Moreover, it is a chronic condition, and spontaneous recovery is rare. Intramuscular injections of Botulinum Toxin (BoNT) are routinely used as HFS treatment.

Methods: We reviewed published articles between 1991 and 2021 regarding the effectiveness and safety of BoNT in HFS as well as any reported differences among BoNT formulations.

Results: The efficacy of BoNT for HFS treatment ranged from 73% to 98.4%. The mean duration of the effect was around 12 weeks. Effectiveness did not decrease over time. Adverse effects were usually mild and transient. The efficacy and tolerability of the different preparations appeared to be similar. Among the studies, dosage, injected muscles, intervals of treatment, and rating scales were variable, thus leading to challenges in comparing the results.

Conclusions: BoNT was the treatment of choice for HFS due to its efficacy and safety profile. Further studies are needed to investigate the factors that influence the outcome, including the optimal timing of treatment, injection techniques, dosage, and the best selection criteria for formulations.

Keywords: BoNT; abobotulinum toxin; botulinum toxin; hemifacial spasm; onabotulinum toxin; spasm.

PubMed Disclaimer

Conflict of interest statement

N.T. declares speaking honoraria and travel expenses for attending meetings from Merz and Dysport. M.F., P.N., L.P. and S.S. declare no conflict of interest.

Figures

Figure 1
Figure 1
Most frequent treated muscles in hemifacial spasm.
See this image and copyright information in PMC

References

    1. Yaltho T.C., Jankovic J. The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms. Mov. Disord. 2011;26:1582–1592. doi: 10.1002/mds.23692. - DOI - PubMed
    1. Jitpimolmard S., Tiamkao S., Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: A report of 175 cases. J. Neurol. Neurosurg. Psychiatry. 1998;64:751–757. doi: 10.1136/jnnp.64.6.751. - DOI - PMC - PubMed
    1. DeFazio G., Abbruzzese G., Girlanda P., Vacca L., Currà A., De Salvia R., Marchese R., Raineri R., Roselli F., Livrea P., et al. Botulinum toxin A treatment for primary hemifacial spasm: A 10-year multicenter study. Arch. Neurol. 2002;59:418–420. doi: 10.1001/archneur.59.3.418. - DOI - PubMed
    1. Bentivoglio A.R., Fasano A., Ialongo T., Soleti F., Lo Fermo S., Albanese A. Outcome predictors, ef-ficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur. J. Neurol. 2009;16:392–398. doi: 10.1111/j.1468-1331.2008.02507.x. - DOI - PubMed
    1. Heuser K., Kerty E., Eide P.K., Cvancarova M., Dietrichs E. Microvascular decompression for hemifacial spasm: Postoperative neurologic follow-up and evaluation of life quality. Eur. J. Neurol. 2007;14:335–340. doi: 10.1111/j.1468-1331.2006.01670.x. - DOI - PubMed

MeSH terms

Substances